Cargando…

Temporary cognitive impairment related to administration of newly developed anticholinergic medicines for overactive bladder: two case reports

BACKGROUND: Cognitive impairment is one of the side effects of using anticholinergic medicines for overactive bladder; however, its incidence has not been fully reported. We experienced two elderly Japanese patients with overactive bladder who had temporary cognitive impairment caused by anticholine...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiota, Takako, Torimoto, Kazumasa, Momose, Hitoshi, Nakamuro, Takuya, Mochizuki, Hiroshi, Kumamoto, Hiromi, Hirayama, Akihide, Fujimoto, Kiyohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180548/
https://www.ncbi.nlm.nih.gov/pubmed/25252702
http://dx.doi.org/10.1186/1756-0500-7-672
_version_ 1782337237129625600
author Shiota, Takako
Torimoto, Kazumasa
Momose, Hitoshi
Nakamuro, Takuya
Mochizuki, Hiroshi
Kumamoto, Hiromi
Hirayama, Akihide
Fujimoto, Kiyohide
author_facet Shiota, Takako
Torimoto, Kazumasa
Momose, Hitoshi
Nakamuro, Takuya
Mochizuki, Hiroshi
Kumamoto, Hiromi
Hirayama, Akihide
Fujimoto, Kiyohide
author_sort Shiota, Takako
collection PubMed
description BACKGROUND: Cognitive impairment is one of the side effects of using anticholinergic medicines for overactive bladder; however, its incidence has not been fully reported. We experienced two elderly Japanese patients with overactive bladder who had temporary cognitive impairment caused by anticholinergic medicines. CASE PRESENTATION: The first case was a 79-year-old female patient to whom imidafenacin (0.2 mg) was administered daily to control her frequent micturition and urgency. She was taking the following medicines: etizolam, triazolam, captopril, bisoprolol, and amlodipine besylate. Her Hasegawa dementia rating scale-revised was impaired from 26/30 to 17/30 and recovered to 25/30 after the imidafenacin treatment was stopped. The second case was an 82-year-old female patient to whom imidafenacin (0.2 mg) was administered daily for frequent micturition and urgency. She was taking the following medicines: losartan potassium and clenbuterol. Her Hasegawa dementia rating scale-revised decreased from 28/30 to 19/30 and recovered to 24/30 after the imidafenacin treatment was stopped. In our patients who were taking multiple medicines, there is a possibility that medicines other than anticholinergics may have caused cognitive impairment. We need to keep in mind that many elderly people take multiple medicines because of comorbidity. CONCLUSIONS: Anticholinergic medicines can cause cognitive impairment in elderly people, and attention should be paid to cognition when elderly overactive bladder patients are treated with anticholinergic medicines.
format Online
Article
Text
id pubmed-4180548
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41805482014-10-03 Temporary cognitive impairment related to administration of newly developed anticholinergic medicines for overactive bladder: two case reports Shiota, Takako Torimoto, Kazumasa Momose, Hitoshi Nakamuro, Takuya Mochizuki, Hiroshi Kumamoto, Hiromi Hirayama, Akihide Fujimoto, Kiyohide BMC Res Notes Case Report BACKGROUND: Cognitive impairment is one of the side effects of using anticholinergic medicines for overactive bladder; however, its incidence has not been fully reported. We experienced two elderly Japanese patients with overactive bladder who had temporary cognitive impairment caused by anticholinergic medicines. CASE PRESENTATION: The first case was a 79-year-old female patient to whom imidafenacin (0.2 mg) was administered daily to control her frequent micturition and urgency. She was taking the following medicines: etizolam, triazolam, captopril, bisoprolol, and amlodipine besylate. Her Hasegawa dementia rating scale-revised was impaired from 26/30 to 17/30 and recovered to 25/30 after the imidafenacin treatment was stopped. The second case was an 82-year-old female patient to whom imidafenacin (0.2 mg) was administered daily for frequent micturition and urgency. She was taking the following medicines: losartan potassium and clenbuterol. Her Hasegawa dementia rating scale-revised decreased from 28/30 to 19/30 and recovered to 24/30 after the imidafenacin treatment was stopped. In our patients who were taking multiple medicines, there is a possibility that medicines other than anticholinergics may have caused cognitive impairment. We need to keep in mind that many elderly people take multiple medicines because of comorbidity. CONCLUSIONS: Anticholinergic medicines can cause cognitive impairment in elderly people, and attention should be paid to cognition when elderly overactive bladder patients are treated with anticholinergic medicines. BioMed Central 2014-09-25 /pmc/articles/PMC4180548/ /pubmed/25252702 http://dx.doi.org/10.1186/1756-0500-7-672 Text en © Shiota et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Shiota, Takako
Torimoto, Kazumasa
Momose, Hitoshi
Nakamuro, Takuya
Mochizuki, Hiroshi
Kumamoto, Hiromi
Hirayama, Akihide
Fujimoto, Kiyohide
Temporary cognitive impairment related to administration of newly developed anticholinergic medicines for overactive bladder: two case reports
title Temporary cognitive impairment related to administration of newly developed anticholinergic medicines for overactive bladder: two case reports
title_full Temporary cognitive impairment related to administration of newly developed anticholinergic medicines for overactive bladder: two case reports
title_fullStr Temporary cognitive impairment related to administration of newly developed anticholinergic medicines for overactive bladder: two case reports
title_full_unstemmed Temporary cognitive impairment related to administration of newly developed anticholinergic medicines for overactive bladder: two case reports
title_short Temporary cognitive impairment related to administration of newly developed anticholinergic medicines for overactive bladder: two case reports
title_sort temporary cognitive impairment related to administration of newly developed anticholinergic medicines for overactive bladder: two case reports
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180548/
https://www.ncbi.nlm.nih.gov/pubmed/25252702
http://dx.doi.org/10.1186/1756-0500-7-672
work_keys_str_mv AT shiotatakako temporarycognitiveimpairmentrelatedtoadministrationofnewlydevelopedanticholinergicmedicinesforoveractivebladdertwocasereports
AT torimotokazumasa temporarycognitiveimpairmentrelatedtoadministrationofnewlydevelopedanticholinergicmedicinesforoveractivebladdertwocasereports
AT momosehitoshi temporarycognitiveimpairmentrelatedtoadministrationofnewlydevelopedanticholinergicmedicinesforoveractivebladdertwocasereports
AT nakamurotakuya temporarycognitiveimpairmentrelatedtoadministrationofnewlydevelopedanticholinergicmedicinesforoveractivebladdertwocasereports
AT mochizukihiroshi temporarycognitiveimpairmentrelatedtoadministrationofnewlydevelopedanticholinergicmedicinesforoveractivebladdertwocasereports
AT kumamotohiromi temporarycognitiveimpairmentrelatedtoadministrationofnewlydevelopedanticholinergicmedicinesforoveractivebladdertwocasereports
AT hirayamaakihide temporarycognitiveimpairmentrelatedtoadministrationofnewlydevelopedanticholinergicmedicinesforoveractivebladdertwocasereports
AT fujimotokiyohide temporarycognitiveimpairmentrelatedtoadministrationofnewlydevelopedanticholinergicmedicinesforoveractivebladdertwocasereports